Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



June 2012, Volume 42 Number 6 , p 10 - 10



Brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, was recently tested for safety and efficacy for treating moderate-to-severe plaque psoriasis. Patients with a score of 12 or higher on the psoriasis area and severity index (PASI) and with 10% or more of their body surface area affected by psoriasis were randomly assigned to receive either brodalumab or a placebo. The primary end point of this study was to improve baseline PASI percentages.At week 12, the mean percentage improvements in the PASI score were 45% among patients receiving 70 mg of brodalumab, 85.9% for those receiving 140 mg, and 86.3% for those receiving 210 mg. The placebo group had a 16% mean improvement score. Researchers concluded that brodalumab significantly improved plaque psoriasis during this 12-week phase II trial study, conducted to determine common, short-term adverse reactions and risks in patients with plaque psoriasis.Source: Papp KA, Leonardi C, Menter A, et al. Brodalumab, an

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: